

Paolo Bruzzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6163682/publications.pdf>

Version: 2024-02-01

161
papers

14,367
citations

23567

58
h-index

19749

117
g-index

161
all docs

161
docs citations

161
times ranked

16824
citing authors

#	ARTICLE	IF	CITATIONS
1	Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1â€² Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial. <i>Annals of Surgical Oncology</i> , 2022, 29, 5732-5744.	1.5	43
2	Reinterpreting Clinical Trials in Children With Multiple Sclerosis Using a Bayesian Approach. <i>JAMA Neurology</i> , 2022, 79, 821.	9.0	5
3	Identification of a Prognostic Signature Based on the Expression of Genes Related to the Insulin Pathway in Early Breast Cancer. <i>Breast Care</i> , 2021, 16, 299-306.	1.4	2
4	Correlation between outcome and extent of residual disease in the sentinel node after neoadjuvant chemotherapy in clinically fine-needle proven node-positive breast cancer patients. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1920-1927.	1.0	4
5	Prognostic factors in chronic subdural hematoma: results from a monocentric consecutive surgical series of 605 patients. <i>Journal of Neurosurgical Sciences</i> , 2021, 65, 14-23.	0.6	2
6	NEONOD 2: Rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapy. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100496.	1.1	14
7	Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700). <i>Oncology</i> , 2020, 98, 763-770.	1.9	9
8	Congenital Muscular Mitral-Aortic Discontinuity Identified in Patients With Obstructiveâ€²Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2238-2247.	2.8	15
9	Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 61-68.	2.5	15
10	Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1566.	2.4	26
11	Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040). , 2019, 7, 96.		34
12	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â€²298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019, 393, 1440-1452.	13.7	260
13	Role of Preoperative Cardiovascular Magnetic Resonance in Planning Ventricular Septal Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2019, 123, 1517-1526.	1.6	18
14	Different View on Larynx Preservation Evidence-Based Treatment Recommendations. <i>Journal of Clinical Oncology</i> , 2018, 36, 1376-1377.	1.6	14
15	Leucocytes telomere length and breast cancer risk/ susceptibility: A case-control study. <i>PLoS ONE</i> , 2018, 13, e0197522.	2.5	8
16	Comparison of coronary flow reserve estimated by dynamic radionuclide SPECT and multi-detector x-ray CT. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 1712-1721.	2.1	10
17	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. <i>European Journal of Cancer</i> , 2017, 71, 34-42.	2.8	39
18	Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: a Possible Role for RANK/RANKL Pathway. <i>Scientific Reports</i> , 2017, 7, 14159.	3.3	14

#	ARTICLE	IF	CITATIONS
19	The urgent need to improve the tools to assess clinical benefit and value of cancer treatment. <i>European Journal of Cancer</i> , 2017, 83, 324-328.	2.8	10
20	Peripherally inserted central catheters (PICCs) in cancer patients under chemotherapy: A prospective study on the incidence of complications and overall failures. <i>Journal of Surgical Oncology</i> , 2016, 113, 708-714.	1.7	94
21	Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM). <i>ESMO Open</i> , 2016, 1, e000109.	4.5	2
22	Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA). <i>Journal of Epidemiology and Community Health</i> , 2016, 70, 741-745.	3.7	138
23	SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes. <i>Breast</i> , 2016, 30, 197-200.	2.2	42
24	Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 79-86.	2.5	20
25	A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2061-2071.	6.4	27
26	Menstrual patterns, fertility and main pregnancy outcomes after allogeneic haematopoietic stem cell transplantation. <i>Journal of Obstetrics and Gynaecology</i> , 2016, 36, 783-788.	0.9	16
27	Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancer. <i>Scientific Reports</i> , 2016, 6, 19569.	3.3	43
28	5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 117-126.	2.5	12
29	Sentinel Lymph Node Biopsy Versus Axillary Dissection in Node-Negative Early-Stage Breast Cancer: 15-Year Follow-Up Update of a Randomized Clinical Trial. <i>Annals of Surgical Oncology</i> , 2016, 23, 2494-2500.	1.5	45
30	Pegfilgrastim administration after 24 or 72 or 96h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial. <i>Supportive Care in Cancer</i> , 2016, 24, 1285-1294.	2.2	17
31	Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients. <i>Oncotarget</i> , 2016, 7, 26465-26479.	1.8	23
32	Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1036-1043.	7.0	31
33	THERAPY OF ENDOCRINE DISEASE: Outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. <i>European Journal of Endocrinology</i> , 2015, 172, R227-R239.	3.7	114
34	Added prognostic value of ischaemic threshold in radionuclide myocardial perfusion imaging: a common-sense integration of exercise tolerance and ischaemia severity. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 750-760.	6.4	5
35	Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 405-413.	2.5	38
36	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2x2 factorial, randomised phase 3 trial. <i>Lancet</i> , The, 2015, 385, 1863-1872.	13.7	164

#	ARTICLE	IF	CITATIONS
37	Refining sorafenib therapy: lessons from clinical practice. <i>Future Oncology</i> , 2015, 11, 449-465.	2.4	17
38	Transaortic Chordal Cutting. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1687-1696.	2.8	141
39	Referral of Ovarian Cancer Patients for Genetic Counselling by Oncologists: Need for Improvement. <i>Public Health Genomics</i> , 2015, 18, 225-232.	1.0	23
40	Can we measure long-term treatment effects in multiple sclerosis?. <i>Nature Reviews Neurology</i> , 2015, 11, 176-182.	10.1	55
41	Clinical Application of Micronucleus Test: A Case-Control Study on the Prediction of Breast Cancer Risk/Susceptibility. <i>PLoS ONE</i> , 2014, 9, e112354.	2.5	19
42	Adult Advanced Chronic Lymphocytic Leukemia: Computational Analysis of Whole-Body CT Documents a Bone Structure Alteration. <i>Radiology</i> , 2014, 271, 805-813.	7.3	24
43	Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies. <i>Journal of Clinical Oncology</i> , 2014, 32, 3883-3891.	1.6	194
44	TOSCA â€” first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 182.	2.7	62
45	Divergent determinants of ¹⁸ Fâ€”NaF uptake and visible calcium deposition in large arteries: relationship with Framingham risk score. <i>International Journal of Cardiovascular Imaging</i> , 2014, 30, 439-447.	1.5	47
46	Predictive and prognostic value of early response assessment using ¹⁸ Fâ€”FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 299-307.	2.3	27
47	The FMR1 CGG repeat test is not a candidate prescreening tool for identifying women with a high probability of being carriers of BRCA mutations. <i>European Journal of Human Genetics</i> , 2014, 22, 280-282.	2.8	6
48	Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 675-683.	7.7	169
49	Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase II study from the Italian Sarcoma Group. <i>European Journal of Cancer</i> , 2014, 50, 784-792.	2.8	80
50	Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. <i>BMC Cancer</i> , 2013, 13, 164.	2.6	19
51	Antioxidant supplement and long-term reduction of recurrent adenomas of the large bowel. A double-blind randomized trial. <i>Journal of Gastroenterology</i> , 2013, 48, 698-705.	5.1	27
52	MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. <i>Lancet Neurology</i> , The, 2013, 12, 669-676.	10.2	234
53	Effectiveness of a project to prevent HIV vertical transmission in the Republic of Congo. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1862-1871.	3.0	20
54	Identification and Validation of a New Set of Five Genes for Prediction of Risk in Early Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 9686-9702.	4.1	18

#	ARTICLE	IF	CITATIONS
55	Doseâ€Dense FEC Followed by Doseâ€Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study. <i>Oncologist</i> , 2013, 18, 924-925.	3.7	0
56	Body Mass Index and Prognosis of Metastatic Breast Cancer Patients Receiving First-Line Chemotherapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1862-1867.	2.5	22
57	Efficacy of Normal Saline Versus Heparinized Saline Solution for Locking Catheters of Totally Implantable Long-Term Central Vascular Access Devices in Adult Cancer Patients. <i>Cancer Nursing</i> , 2012, 35, E35-E42.	1.5	73
58	Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2593-2600.	1.6	218
59	Screening women at intermediate risk: harm or charm?. <i>European Journal of Radiology</i> , 2012, 81, S116-S117.	2.6	2
60	CMV Infection after Transplant from Cord Blood Compared to Other Alternative Donors: The Importance of Donor-Negative CMV Serostatus. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 92-99.	2.0	31
61	Reporting of subgroup analyses from clinical trials. <i>Lancet Neurology</i> , The, 2012, 11, 747.	10.2	15
62	Comments on â€œevidence for acute neurotoxicity after chemotherapyâ€: <i>Annals of Neurology</i> , 2011, 69, 1064-1064.	5.3	0
63	Micronucleus test for radiation biodosimetry in mass casualty events: Evaluation of visual and automated scoring. <i>Radiation Measurements</i> , 2011, 46, 169-175.	1.4	18
64	Vatalanib in Advanced Colorectal Cancer: Two Studies With Identical Results. <i>Journal of Clinical Oncology</i> , 2011, 29, 1938-1940.	1.6	26
65	Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 2144-2149.	1.6	167
66	Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1529-1539.	6.3	27
67	Intermediate Endpoints of Primary Systemic Therapy in Breast Cancer Patients. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 142-146.	2.1	8
68	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 147-151.	2.1	61
69	Clinical Performance of the (1,3)- β -D-Glucan Assay in Early Diagnosis of Nosocomial Candida Bloodstream Infections. <i>Vaccine Journal</i> , 2011, 18, 2113-2117.	3.1	53
70	CTLA-4 +49A>G polymorphism of recipients of HLA-matched sibling allogeneic stem cell transplantation is associated with survival and relapse incidence. <i>Annals of Hematology</i> , 2010, 89, 613-618.	1.8	18
71	Reply to M.L. Berger et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e345-e345.	1.6	1
72	Phase II Study of Asparagine-Glycine-Arginineâ€“Human Tumor Necrosis Factor β , a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2604-2611.	1.6	111

#	ARTICLE	IF	CITATIONS
73	The daily diary and the questionnaire are not equivalent for the evaluation of bowel habits. Digestive and Liver Disease, 2010, 42, 99-102.	0.9	12
74	Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. European Journal of Cancer, 2010, 46, 198-206.	2.8	50
75	Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy. Circulation, 2009, 119, 1703-1710.	1.6	296
76	Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug Approval. Journal of Clinical Oncology, 2009, 27, 5868-5873.	1.6	88
77	Is there a subset of patients with preoperatively diagnosed N2 non-small cell lung cancer who might benefit from surgical resection?. Journal of Thoracic and Cardiovascular Surgery, 2009, 138, 849-858.	0.8	13
78	Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach. Annals of Neurology, 2009, 65, 268-275.	5.3	206
79	High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies. International Journal of Cancer, 2009, 124, 333-338.	5.1	36
80	Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer. Breast Cancer Research and Treatment, 2009, 115, 131-136.	2.5	12
81	Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and Î²2-microglobulin downregulation in breast cancer. Human Immunology, 2009, 70, 492-495.	2.4	12
82	Excellent Outcome With Reduced Treatment for Infants With Disseminated Neuroblastoma Without MYCN Gene Amplification. Journal of Clinical Oncology, 2009, 27, 1034-1040.	1.6	134
83	Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase II study. Lancet Oncology, The, 2009, 10, 489-500.	10.7	458
84	Diagnostic Accuracy of Computed Tomographic Colonography for the Detection of Advanced Neoplasia in Individuals at Increased Risk of Colorectal Cancer. JAMA - Journal of the American Medical Association, 2009, 301, 2453.	7.4	199
85	Will Rogers phenomenon in multiple sclerosis. Annals of Neurology, 2008, 64, 428-433.	5.3	80
86	Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial); Tj ETQq0 0 ZrgBT /Overlock 10 TF		
87	HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials. Journal of the National Cancer Institute, 2008, 100, 14-20.	6.3	344
88	Non-drug industry funded research. BMJ: British Medical Journal, 2008, 336, 1-2.	2.3	16
89	Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions. Oncologist, 2008, 13, 1137-1148.	3.7	31
90	Retrospective Study of Childhood Ganglioneuroma. Journal of Clinical Oncology, 2008, 26, 1710-1716.	1.6	128

#	ARTICLE	IF	CITATIONS
91	An Unconventional Cancer Treatment Lacking Clinical Efficacy Remains Available to Italian Cancer Patients. <i>Tumori</i> , 2008, 94, 830-832.	1.1	1
92	Re: Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1050-1051.	6.3	3
93	Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 405-12.	7.4	705
94	Prognostic Effect of DNA Aneuploidy from Bladder Washings in Superficial Bladder Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 979-983.	2.5	7
95	Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 2372-2380.	27.0	679
96	Metabolic Treatment with L-Carnitine in Acute Anterior ST Segment Elevation Myocardial Infarction. <i>Cardiology</i> , 2006, 106, 215-223.	1.4	42
97	Thymoglobulin Prevents Chronic Graft-versus-Host Disease, Chronic Lung Dysfunction, and Late Transplant-Related Mortality: Long-Term Follow-Up of a Randomized Trial in Patients Undergoing Unrelated Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 560-565.	2.0	326
98	BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomyacin B. <i>Blood</i> , 2006, 107, 1591-1598.	1.4	53
99	The General Practitioner's Management of Patients With a New Diagnosis of Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 87.	2.2	2
100	Molecular epidemiology: New rules for new tools?. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2006, 600, 3-11.	1.0	6
101	Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2006, 24, 3623-3628.	1.6	178
102	Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. <i>Endocrine-Related Cancer</i> , 2006, 13, 921-930.	3.1	74
103	Lack of Benefit of Maintenance Paclitaxel in First-Line Chemotherapy in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 3912-3918.	1.6	85
104	Actual and preferred place of death of cancer patients. Results from the Italian survey of the dying of cancer (ISDOC). <i>Journal of Epidemiology and Community Health</i> , 2006, 60, 412-416.	3.7	193
105	Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. <i>Blood</i> , 2005, 105, 2601-2607.	1.4	147
106	Survival of metastatic breast carcinoma patients over a 20-year period. <i>Cancer</i> , 2005, 104, 1742-1750.	4.1	253
107	Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. <i>Cancer</i> , 2005, 104, 2099-2103.	4.1	50
108	The distribution of magnetic resonance imaging response to interferon- β in multiple sclerosis. <i>Journal of Neurology</i> , 2005, 252, 1455-1458.	3.6	23

#	ARTICLE	IF	CITATIONS
109	Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2005, 23, 5117-5125.	1.6	114
110	Bevacizumab Plus Fluorouracil: The Value of Being Part of a Developing Story. <i>Journal of Clinical Oncology</i> , 2005, 23, 3660-3662.	1.6	12
111	Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1724-1733.	6.3	146
112	The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1076-1080.	2.8	215
113	False-Positive Galactomannan PlateliaAspergillusTest Results for Patients Receiving Piperacillin-Tazobactam. <i>Clinical Infectious Diseases</i> , 2004, 38, 913-916.	5.8	240
114	Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma. <i>Cancer</i> , 2004, 101, 704-712.	4.1	105
115	Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas. <i>International Journal of Cancer</i> , 2004, 109, 680-684.	5.1	159
116	Twelve-year experience with left atrial resection in the treatment of non-small cell lung cancer. <i>Annals of Thoracic Surgery</i> , 2004, 78, 234-237.	1.3	72
117	An extended assessment of bowel habits in a general population. <i>World Journal of Gastroenterology</i> , 2004, 10, 713.	3.3	41
118	Cancer of the nasopharynx. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 45, 199-214.	4.4	50
119	Major and minor salivary glands tumours. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 45, 215-225.	4.4	68
120	Malignant melanoma. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 47, 35-63.	4.4	55
121	Interobserver agreement in the histologic diagnosis of colorectal polyps the experience of the multicenter adenoma colorectal study (SMAC). <i>Journal of Clinical Epidemiology</i> , 2003, 56, 209-214.	5.0	83
122	Effect of a palliative home care team on hospital admissions among patients with advanced cancer. <i>Palliative Medicine</i> , 2003, 17, 315-321.	3.1	74
123	Association of Breast Cancer and Polymorphisms of Interleukin-10 and Tumor Necrosis Factor- β Genes. <i>Clinical Chemistry</i> , 2003, 49, 1664-1667.	3.2	66
124	Disseminated Neuroblastoma in Children Older Than One Year at Diagnosis: Comparable Results With Three Consecutive High-Dose Protocols Adopted by the Italian Co-Operative Group for Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 1592-1601.	1.6	153
125	Title is missing!. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, 359-365.	2.0	36
126	Time to Progression in Metastatic Breast Cancer Patients Treated With Epirubicin Is Not Improved by the Addition of Either Cisplatin or Lonidamine: Final Results of a Phase III Study With a Factorial Design. <i>Journal of Clinical Oncology</i> , 2002, 20, 4150-4159.	1.6	69

#	ARTICLE	IF	CITATIONS
127	MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. <i>Neurology</i> , 2002, 58, 417-421.	1.1	56
128	Risk associated with pregnancy in hypertrophic cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1864-1869.	2.8	174
129	Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. <i>Cancer</i> , 2002, 95, 228-235.	4.1	9
130	Bladder cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 41, 89-106.	4.4	32
131	Cancer of the oropharynx. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 41, 107-122.	4.4	63
132	Objective Response to Treatment as a Potential Surrogate Marker of Survival in Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 2002, 963, 144-147.	3.8	7
133	Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). <i>Blood</i> , 2001, 98, 2942-2947.	1.4	487
134	Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial. <i>Journal of Cellular Biochemistry</i> , 2000, 76, 311-321.	2.6	10
135	Magnitude of Left Ventricular Hypertrophy and Risk of Sudden Death in Hypertrophic Cardiomyopathy. <i>New England Journal of Medicine</i> , 2000, 342, 1778-1785.	27.0	998
136	Phase II Study of Combined Immunotherapy, Chemotherapy, and Radiotherapy in the Postoperative Treatment of Advanced Nonâ€‘Smallâ€‘Cell Lung Cancer. <i>Journal of Immunotherapy</i> , 2000, 23, 161-167.	2.4	15
137	Cardiotoxicity of Epirubicin/Paclitaxelâ€‘Containing Regimens: Role of Cardiac Risk Factors. <i>Journal of Clinical Oncology</i> , 1999, 17, 3596-3602.	1.6	89
138	Infective Endocarditis in Hypertrophic Cardiomyopathy. <i>Circulation</i> , 1999, 99, 2132-2137.	1.6	125
139	Do patients with rectosigmoid adenomas 5 mm or less in diameter need total colonoscopy?. <i>Gastrointestinal Endoscopy</i> , 1999, 50, 314-321.	1.0	20
140	Novel germline APC variants in patients with multiple adenomas. <i>Genes Chromosomes and Cancer</i> , 1998, 22, 257-267.	2.8	33
141	Prognostic role of lymph-node level involvement in patients undergoing axillary dissection for breast cancer. <i>European Journal of Surgical Oncology</i> , 1998, 24, 104-109.	1.0	36
142	Mathematical modelling of pilot-plant photomineralization of chlorophenols in aqueous solution, by photocatalytic membranes immobilizing titanium dioxide. <i>Chemosphere</i> , 1997, 34, 41-49.	8.2	21
143	Distal hyperplastic polyps do not predict proximal adenomas: results from a multicentric study of colorectal adenomas. <i>Gastrointestinal Endoscopy</i> , 1997, 46, 124-130.	1.0	42
144	Pilot-plant photomineralization of dichloromethane and tetrachloroethene in aqueous solution, by photocatalytic membranes immobilizing titanium dioxide and photopromoters. <i>Chemosphere</i> , 1996, 33, 1531-1542.	8.2	13

#	ARTICLE	IF	CITATIONS
145	Mathematical modelling of photomineralization of phenols in aqueous solution, by photocatalytic membranes immobilizing titanium dioxide. <i>Chemosphere</i> , 1996, 33, 2159-2173.	8.2	30
146	A Multicenter Study of Colorectal Adenomas Rationale, Objectives, Methods and Characteristics of the Study Cohort. <i>Tumori</i> , 1995, 81, 157-163.	1.1	8
147	Wolfe's mammographic patterns in women with Gross Cystic Disease of the breast. <i>Journal of Clinical Epidemiology</i> , 1995, 48, 969-976.	5.0	3
148	Effects of l-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the l-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial. <i>Journal of the American College of Cardiology</i> , 1995, 26, 380-387.	2.8	152
149	Steroid biochemistry and categorization of breast cyst fluid: relation to breast cancer risk. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1994, 49, 333-339.	2.5	30
150	The impact of received dose intensity on the outcome of advanced ovarian cancer. <i>European Journal of Cancer</i> , 1993, 29, 181-184.	2.8	32
151	Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. <i>European Journal of Cancer</i> , 1993, 29, 1658-1663.	2.8	28
152	Treatment of Advanced Squamous-Cell Carcinoma of the Head and Neck with Alternating Chemotherapy and Radiotherapy. <i>New England Journal of Medicine</i> , 1992, 327, 1115-1121.	27.0	285
153	Attributable risks for oesophageal cancer in Northern Italy. <i>European Journal of Cancer</i> , 1992, 28, 1167-1171.	2.8	66
154	Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. <i>Cancer</i> , 1992, 70, 1625-1633.	4.1	97
155	Anthropometric variables and risk of breast cancer. <i>International Journal of Cancer</i> , 1990, 45, 397-402.	5.1	43
156	Some Further Consideration on the Role of Oral Contraceptives in Breast Carcinogenesis. <i>Tumori</i> , 1990, 76, 220-224.	1.1	7
157	The Relationship Between Oral Contraceptive Use, Cancer and Vascular Disease. <i>Drug Safety</i> , 1990, 5, 436-446.	3.2	17
158	Thymidine labelling index as prognostic factor in resected non-small cell lung cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1990, 26, 622-625.	0.7	23
159	Follow-up Studies of Patients with Categorized Breast Cysts.. <i>Annals of the New York Academy of Sciences</i> , 1990, 586, 43-48.	3.8	4
160	Population attributable risk for endometrial cancer in Northern Italy. <i>European Journal of Cancer & Clinical Oncology</i> , 1989, 25, 1451-1456.	0.7	32
161	ESTIMATING THE POPULATION ATTRIBUTABLE RISK FOR MULTIPLE RISK FACTORS USING CASE-CONTROL DATA. <i>American Journal of Epidemiology</i> , 1985, 122, 904-914.	3.4	1,122